FDA批准用于甲型肝炎和麻疹暴露的新药

StephenW

FDA Approves New Drug For Hepatitis A And Measles Exposure
Robin Seaton Jefferson
Robin Seaton Jefferson
Contributor i
Retirement

The US Food and Drug Administration (FDA) has approved a new drug for people who have been exposed to measles and hepatitis A viruses. This could be especially good news for older adults who are more likely to suffer from weakened immune systems and thus have more difficulty fighting off infections.

Grifols, a global health care producer of plasma, diagnostic and pharmaceutical products with corporate headquarters in Sant Cugat del Valles, Barcelonathe and industrial facilities all over the world, discovered the treatment. The company said in a news release that their formulation, GamaSTAN®, is the only immune globulin product available in the United States to protect against hepatitis A virus (HAV) and measles after exposure.

"Vaccination, while a valuable option for hepatitis A and measles post-exposure prophylaxis, may take several weeks to take effect as your immune system works to build the antibodies it needs to fight these viruses," said Stephen Scholand, M.D., infectious disease specialist at MidState Medical Center, said in a statement. "Immune globulins such as GamaSTAN® have been a valuable treatment option for many decades because they offer immediate and rapid protection with antibodies that fight infection."

The CDC recommends an immune globulin for HAV post-exposure treatment for people over 40, the company said. “The CDC also recommends that immune globulin should be used for children aged less than 12 months, immunocompromised persons, persons with chronic liver disease and persons who are allergic to the vaccine or a vaccine component. When administered within 2 weeks after exposure to HAV, immune globulin is 80 to 90 percent effective in preventing hepatitis A infection.”

Woman receiving vaccination.

According to the National Center for Biotechnology Information (NCBI) and the National Institutes of Health (NIH), immune globulin treats immune system problems and helps prevent infections or lessens their severity. It contains antibodies that strengthen the immune system. Immune globulin injection belongs to a group of medicines known as immunizing agents. It can also treat disorders that involve the muscle and nervous systems.
MORE FROM FORBES

StephenW

FDA批准用于甲型肝炎和麻疹暴露的新药
罗宾西顿杰斐逊
罗宾西顿杰斐逊
贡献者我
退休

美国食品和药物管理局（FDA）批准了一种新药，用于接触麻疹和甲型肝炎病毒的人。对于更容易患免疫系统较弱的老年人来说，这可能是一个特别好的消息，因此更难以抵御感染。

Grifols是一家血浆，诊断和医药产品的全球医疗保健生产商，公司总部位于Sant Cugat del Valles，Barcelonathe和世界各地的工业设施，他们发现了这种治疗方法。该公司在新闻发布会上表示，他们的配方GamaSTAN®是美国唯一可用于预防接种甲型肝炎病毒（HAV）和麻疹的免疫球蛋白产品。

“疫苗接种虽然是甲型肝炎和麻疹暴露后预防的一个有价值的选择，但可能需要几周的时间才能生效，因为你的免疫系统可以构建抗击这些病毒所需的抗体，”传染病专家医学博士Stephen Scholand说。在MidState医疗中心，在一份声明中说。 “GamaSTAN®等免疫球蛋白几十年来一直是一种有价值的治疗选择，因为它们能够通过抵抗感染的抗体立即提供快速保护。”

该公司表示，疾病预防控制中心建议为40岁以上的人提供免疫球蛋白用于HAV暴露后治疗。 “疾病预防控制中心还建议免疫球蛋白应用于12个月以下的儿童，免疫功能低下者，慢性肝病患者以及对疫苗或疫苗成分过敏的人群。在接触HAV后2周内给药时，免疫球蛋白可有效预防甲型肝炎感染80％至90％。

接种疫苗的妇女。

根据美国国家生物技术信息中心（NCBI）和美国国立卫生研究院（NIH），免疫球蛋白治疗免疫系统问题并有助于预防感染或减轻其严重程度。它含有增强免疫系统的抗体。免疫球蛋白注射剂属于一组称为免疫剂的药物。它还可以治疗涉及肌肉和神经系统的疾病。
更多来自福布斯